GSK · story · 13 November – 14 November
GSK · 3 headlines from 1 outlet, from 13 November 2026 to 14 November 2026.
Pieces report a $2.2bn Zantac settlement and put GSK stock in focus.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
| Outlet | Headlines | Average tone |
|---|---|---|
| AD HOC NEWS | 3 | −0.6 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +1.7 | Patent wins offset by pending Zantac settlement concerns. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| −1.7 | Large litigation settlement, though it ends a long-running legal overhang |
| −1.7 | Share focus on large settlement over drug claims |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.